HC Wainwright Has Negative Estimate for FTH FY2026 Earnings

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) – Research analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of Sensei Biotherapeutics in a research report issued on Wednesday, November 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($15.52) per share for the year, down from their previous estimate of ($13.54). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Sensei Biotherapeutics’ current full-year earnings is ($13.35) per share. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q4 2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.90) EPS, Q4 2027 earnings at ($0.97) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($3.10) EPS and FY2030 earnings at ($3.09) EPS.

Other analysts have also recently issued research reports about the company. Raymond James Financial initiated coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price objective on the stock. TD Cowen started coverage on Sensei Biotherapeutics in a research report on Wednesday, September 9th. They issued a “buy” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. Lifesci Capital upgraded Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, October 15th. Finally, Oppenheimer began coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $56.58.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock opened at $10.65 on Friday. The company has a market capitalization of $275.20 million, a price-to-earnings ratio of -0.08 and a beta of -0.15. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $42.14. The company has a 50-day moving average price of $25.65.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.13).

Institutional Investors Weigh In On Sensei Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp acquired a new position in Sensei Biotherapeutics in the third quarter valued at approximately $9,262,000. Candriam S.C.A. bought a new stake in shares of Sensei Biotherapeutics in the 3rd quarter worth approximately $9,542,000. State of Wyoming bought a new stake in shares of Sensei Biotherapeutics in the 3rd quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Sensei Biotherapeutics by 48.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company’s stock worth $150,000 after purchasing an additional 1,760 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in Sensei Biotherapeutics during the 2nd quarter valued at approximately $307,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Key Sensei Biotherapeutics News

Investors following FTH have been watching these news items:

• Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 price target despite revising estimates lower. MarketBeat report
• Neutral Sentiment: A separate announcement under the name Faeth Therapeutics (Nasdaq: FTH) said management would attend November investor conferences; it may provide investor exposure, but the announcement gave no new business or clinical update. Conference announcement
• Negative Sentiment: HC Wainwright lowered its projected losses for Q4 2026 and each quarter of 2027, as well as its full-year estimates for 2026–2030. For example, its FY2027 EPS estimate moved to a loss of $3.60 from $2.68, and its FY2026 estimate to a loss of $15.52 from $13.54. The broader revisions point to weaker expected earnings and may weigh on the stock. MarketBeat analyst estimates

About Sensei Biotherapeutics

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.